Long-term projections of the harm-benefit trade-off in prostate cancer screening are more favorable than previous short-term estimates.

Publication Type:

Journal Article


Journal of clinical epidemiology, Volume 64, Issue 12, p.1412-7 (2011)


2011, November 2011, Public Health Sciences Division


To project long-term estimates of the number needed to screen (NNS) and the additional number needed to treat (NNT) to prevent one prostate cancer death with prostate-specific antigen (PSA) screening in Europe and in the United States.